Vaccination of immunocompromised patients  by Ljungman, Per
Vaccination of immunocompromised patients
Per Ljungman1,2
1) Department of Haematology, Karolinska University Hospital, 2) Division of Haematology, Department of Medicine Huddinge, Karolinska
Institutet, Stockholm, Sweden
Abstract
Vaccination of immunocompromised patients is challenging both regarding efficacy and safety. True efficacy data are lacking so existing
recommendations are based on immune responses and safety data. Inactivated vaccines can generally be used without risk but the
patients who are most at risk for infectious morbidity and mortality as a result of their severely immunosuppressed state are also those
least likely to respond to vaccination. However, vaccination against pneumococci, Haemophilus influenzae and influenza are generally rec-
ommended. Live vaccines must be used with care because the risk for vaccine-associated disease exists.
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Introduction
Over the past decades, the number of immunocompromised
patients has increased rapidly. These patients are vulnerable
to several infections against which vaccines exist. New vac-
cines have been developed or are in development that
might result in important advantages in reducing infectious
disease morbidity and possibly mortality such as cytomegalo-
virus.
General aspects
The background and characteristics of the immunosup-
pressed states differ between different patient groups. Can-
cer therapy has changed substantially during the past
decades because many new types of therapy including mono-
clonal antibodies and targeted anticancer drugs have been
introduced. Patients undergoing haematopoietic allogeneic
stem cell transplantation (HSCT) are immunocompromised
through different mechanisms, which change during follow-
up after the transplant. The technology of allogeneic HSCT
is developing rapidly and only limited data are available, for
example, in patients who have undergone cord blood or ha-
plo-identical HSCT. Immunity to infectious agents is trans-
ferred by the graft and can be detected in the patient early
after the HSCT but it is usually of a finite duration [1–3].
The immune status of the donor is important for the short-
term transfer of immunity and can be boosted by immuniz-
ing the donor before the transplant combined with early
post-transplant vaccination of the recipient [4,5]. Several
studies have shown that autologous transplant recipients also
lose protective immunity during long-term follow-up [6–8]
and many patients undergoing autologous HSCT for lym-
phoma will have received rituximab or alemtuzumab, which
will influence the responses to vaccination especially during
the first 6 months after transplantation. Immunizations can
be given to solid organ transplant (SOT) candidates either
before the transplant, because the immune response then is
more likely to be less suppressed and the patient more
likely to respond, or after the transplantation [9].
An important caveat regarding vaccination of immunosup-
pressed patients is that no true efficacy data exist, because
the studies have been underpowered to detect differences in
the risk for infection. Therefore recommendations are mainly
based on safety and knowledge about the immune responses
to the different vaccines.
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Non-live vaccines
Pneumococcal vaccines. Pneumococci are important causes of
disease in immunosuppressed patients. In children with leu-
kaemia, the 14-valent polysaccharide vaccine gave suboptimal
antibody responses [10]. Similar results were found with the
23-valent polysaccharide vaccine (PPV23) in patients with
multiple myeloma [11]. Lymphoma patients with poor anti-
body responses to the polysaccharide vaccine have an
increased risk for severe pneumococcal infections [12].
Patients with chronic lymphocytic leukaemia do respond to
pneumococcal conjugate vaccine but the response rates are
lower than in controls and poorer late in the course of the
disease [13].
Immunization with the PPV23 can elicit antibody responses
from 6 months after HSCT in patients without graft-versus-
host disease (GVHD) but was ineffective in patients with
chronic GVHD [14–16]. The 7-valent pneumococcal conjugate
vaccine (PCV7; Prevnar) has been evaluated in several studies
[17–19] showing improved responses compared with polysac-
charide vaccines. However, repeated doses are needed to
obtain long-lasting responses. It was also shown that a dose of
PPV23 given 9 months after the first PCV7 dose increased the
response rates and extended the serotype coverage [19].
Studies with PCV7 have also been performed in children
showing good immune responses [20,21]. Current recommen-
dations are to give three doses of a pneumococcal conjugate
vaccine starting at 3–4 months after HSCT followed by either
a PPV23 dose in patients without GVHD or a conjugate vac-
cine dose in patients with chronic GVHD [22,23] .
Autologous HSCT patients are less prone than allogeneic
HSCT patients to develop severe infections with pneumo-
cocci. The response to a single dose of pneumococcal poly-
saccharide vaccine was poor regardless of the stem cell
source [8]. Vaccination with the PCV7 could induce protec-
tive antibody levels in >60% of the patients [24].
Both candidates awaiting a SOT and transplant recipients
are at an increased risk for invasive pneumococcal infection
[25]. Protective titres can be obtained in most candidates
after vaccination with PPV23. Immunizations against pneumo-
cocci should therefore be considered for children waiting for
SOT [26,27]. Kumar et al. [28] compared in a double-blind,
randomized study a conjugate and a polysaccharide vaccine
in adult renal transplant recipients and found no difference
between the two vaccines. Therefore, a single PPV23 dose
remains the standard of care for adults and older children
(>5 years) after SOT [9,29] whereas in children the PCV13
vaccine is recommended [9].
Haemophilus influenzae type b vaccine. Children with cancer
have an increased risk for Haemophilus influenzae type b
(Hib) infection compared with normal children and immuni-
zation with a conjugated Hib vaccine is indicated in children
with cancer. Immunization with Hib conjugate vaccines can
elicit protective immune responses after HSCT [14,30].
Immunization with a Hib vaccine is indicated for allogeneic
HSCT recipients [22,23].
Influenza vaccine. The morbidity of influenza varies in differ-
ent types of immunosuppressed patients. Influenza can be
very severe for HSCT recipients and fatal infections can
develop up to 15 years after HSCT [31,32]. The experience
with the pandemic H1N1 virus showed a pneumonia rate of
33% and a mortality of 6.8% [33]. In SOT patients infected
with the pandemic strain, the risk for pneumonia was 32%
and for mortality was 4% [34].
The timing of vaccination in cancer patients is important
for the response. Children with cancer receiving chemother-
apy have poorer responses to trivalent influenza vaccine than
those who had completed chemotherapy and in healthy con-
trols [35]. Similarly, vaccination against the pandemic H1N1
influenza gave weaker responses in children with ongoing
chemotherapy [36]. Patients with breast cancer vaccinated
during ongoing chemotherapy had significantly lower
responses than healthy controls and had a tendency to a bet-
ter response if vaccinated early after a given chemotherapy
course [37]. Most studies show that adult patients with hae-
matological malignancies respond poorly to vaccination
[11,38,39]. Addition of a second dose to patients with vari-
ous haematological malignancies has given variable results
[40–42]. Vaccination results of patients who have received
monoclonal antibodies for lymphoma are very poor [40,42].
It is therefore not recommended to give influenza vaccine
during the period of intensive chemotherapy such as in
patients with acute leukaemia.
The time after HSCT is important for vaccine efficacy, with
patients vaccinated later after transplantation generally having
better responses [42–45]. During the H1N1 pandemic, sev-
eral studies were performed in HSCT recipients [42,45,46].
The response rates were 48–76% depending on the number
of doses and whether a non-adjuvanted or adjuvanted vaccine
was used. However, despite a suboptimal serological
response, there might be clinical effectiveness of vaccination.
Machado et al. [47] found that influenza vaccination per-
formed at least 6 months after SCT had an 80% efficacy in
preventing influenza. Annual vaccination with the trivalent
influenza vaccine is recommended after allogeneic HSCT,
preferably not started before 6 months after HSCT However,
during an influenza outbreak it can be considered to start
influenza vaccination at the earliest at 3 months after HSCT
but then to give a 2:d dose four weeks after the first dose.
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Because influenza can be severe in patients with end-
stage organ disease, annual influenza vaccination with the
inactivated seasonal influenza vaccine is recommended in
transplant candidates [48]. Results of immunization in SOT
patients vary with their age and adults have poorer antibody
responses than immune competent controls [49–52]. In
contrast, normal responses to influenza immunization are
seen in children [53,54]. It has been suggested that intrader-
mal vaccination can improve the immune response in renal
transplant patients [55]. Magnani et al. [56] reported that
vaccination of heart transplant recipients can reduce the
proportion of patients developing influenza-like illness. In a
retrospective analysis of paediatric liver transplant patients
vaccinated with the pandemic H1N1 vaccine, the frequency
of infection was 4% compared with 25% in unvaccinated
patients [57].
Influenza vaccination is generally recommended to immu-
nocompromised patients. However, it must be recognized
that the protective effectiveness is likely to be low in the
patients who are at highest risk of severe complications from
influenza infection. Immunization of family members and hos-
pital staff is therefore recommended. No data exist for the
live attenuated vaccine and it should not be used.
Tetanus toxoid, diphtheria toxoid, pertussis and inactivated polio-
virus vaccine. Both adults and children with cancer have
poor protective immunity against tetanus [58–60]. The loss
of immunity is related to the intensity of the chemotherapy
administered. Most children respond well to vaccination
after chemotherapy for malignancies [60,61]. However, chil-
dren treated for high-risk acute lymphoblastic leukaemia
had poor responses [62]. In HSCT patients it has been
shown that a new primary schedule with repeated doses is
needed [3,6,8,63,64]. Vaccination with three doses of teta-
nus toxoid, diphtheria toxoid, and inactivated poliovirus
vaccine is therefore recommended after HSCT [22,23].
Because HSCT patients should be viewed as ‘never vacci-
nated’ they should receive full doses of toxoids; the ‘DT’
vaccine.
Vaccination of SOT candidates is recommended either to
complete the primary schedule (young children) or with a
booster dose of Tdap (older children and adults) [9]. Good
responses can also be obtained with booster vaccination
after SOT [65].
Despite the absence of data, it seems logical to recom-
mend an investigation of poliovirus immunity and booster
immunization for immunosuppressed patients travelling to
areas of the world where poliovirus is still endemic. The oral
poliovirus vaccine can induce paralytic disease in immuno-
compromised patients and should not be used.
Transplant patients might be vulnerable to pertussis
although the documentation for severe infections is limited
[66,67]. In young children, it is logical to vaccinate against
pertussis together with diphtheria and tetanus because many
vaccines include a pertussis component (DTaP). The effect of
vaccination with low-dose pertussis (Tdap) has been shown
to be poor in HSCT recipients [68,69]. Pertussis vaccination
can be considered in older children and adults but then it is
preferable to use a vaccine with higher pertussis content
[22,23]. Pertussis vaccination after SOT has not been stud-
ied, but continuation of basic immunization with an acellular
vaccine (in combination with diphtheria and tetanus vaccines)
is recommended [9].
Hepatitis B virus. Several studies have been performed regard-
ing the efficacy of hepatitis B virus (HBV) vaccination in chil-
dren with cancer [70–74]. The response rates varied greatly
from 20 to 80%. In HSCT patients, one study investigated
the start of vaccination based on grade of immune compe-
tence and 64% seroconverted, a rate lower than in age-
matched controls [75]. Loss of pre-existing immunity to HBV
is quite common after HSCT and in patients receiving ther-
apy with anti-B-cell antibodies such as rituximab and can
result in virus re-emergence with or without signs of hepati-
tis. Vaccination of patients with pre-existing immunity to
HBV reduced the risk for virus reactivation [76]. Vaccination
against HBV is recommended after allogeneic HSCT [22,23].
Vaccination for HBV is recommended in HBV-negative
SOT candidates because there is an increased risk of severe
HBV infections in transplant patients. However, the
responses are frequently suboptimal. Besides poor
responses, the antibody levels can decrease rapidly so that
up to 35% of the patients who seroconverted become sero-
negative after liver transplantation [77–79]. Despite the less
than optimal responses, pretransplant immunization is rec-
ommended [9]. Children can achieve good vaccination
responses also after SOT [80].
Vaccinations against HBV with the aim of preventing reac-
tivation in patients transplanted for HBV-induced cirrhosis
have given varying results [81,82]. Intradermal HBV vaccina-
tion might induce an immune response in patients failing
intramuscular vaccination [83].
Hepatitis A virus. Hepatitis A virus can cause decompensa-
tion and death in patients with chronic liver disease.
Patients with chronic liver or renal disease awaiting trans-
plantation are able to respond to vaccination, although the
results are not as good as in normal individuals [84,85].
The combined hepatitis A/B vaccine is potentially useful in
pretransplant immunization.
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Cytomegalovirus vaccine. Cytomegalovirus (CMV) is one of the
most important pathogens in transplant patients. A DNA
plasmid vaccine containing plasmids for glycoprotein B (gB)
and pp65 was, in a phase II study, able to elicit T-cell
responses and reduce the rate of CMV DNAemia [86]. In
SOT recipients, a gB-based vaccine reduced the number of
days of CMV viraemia in seronegative patients receiving
grafts from CMV-seropositive donors [87]. Phase III studies
are in the planning phase.
Papillomavirus vaccine. Immunocompromised patients are at
increased risk for complications driven by human papilloma-
virus infections. The vaccines are safe and efficient in immune
competent individuals but have not yet been studied in these
patients but could be considered [88]. No study has been
performed to show efficacy. There are no data regarding
immunogenicity of vaccination with papillomavirus vaccine in
immunocompromised patients. Indications for vaccination
against papillomavirus could be the same as for the general
population (girls and young women) but it could be argued
that males might also benefit.
Live vaccines
In contrast to the situation with inactivated or subcompo-
nent vaccines, immunization with live vaccines might pose
risks of significant side-effects to immunocompromised
patients. Most published guidelines therefore do not recom-
mend vaccination with these vaccines.
Varicella virus vaccine. Primary varicella infections cause high
mortality in children with cancer and after transplantation.
The existing vaccine was shown to be effective and safe in
children with leukaemia in remission [89]. The frequency of
side-effects from the vaccine is low, and breakthrough vac-
cine disease can usually be treated effectively with acyclovir
[89,90]. The care of varicella seronegative patients is fre-
quently cumbersome because exposure to varicella-infected
individuals is not uncommon and requires prophylactic mea-
sures. Vaccination of seronegative family members is there-
fore recommended if the patient cannot be vaccinated
[22,23]. There are limited data about the use of the varicella
vaccine after allogeneic HSCT but it seems to be safe and
efficacious if given in patients without chronic GVHD or
ongoing immunosuppression [91–93]
Varicella zoster virus (VZV) can also cause severe disease
in patients after SOT. It is therefore important to consider
the vaccination of seronegative candidates. A large study in
more than 700 children before renal transplantation showed
that vaccination reduced the incidence of both varicella and
zoster [94]. Vaccination of VZV seronegative patients after
SOT is not recommended, although some data report that it
can be done safely [95].
Vaccination with the live zoster vaccine is not recom-
mended in immunocompromised patients. However, two
inactivated vaccines are currently undergoing phase III
studies.
MMR. Measles infections in patients with cancer have a high
mortality [96]. Loss of immunity is common in children
treated for leukaemia and in HSCT recipients, especially in
those who were previously vaccinated [62,97,98]. Immuniza-
tion with the measles vaccine might be considered in
patients not receiving active chemotherapy in epidemiologi-
cal situations when the risk for measles is increased. The
reported effect of vaccination varies between different stud-
ies with a seemingly higher response rate in adults than in
children [99–103]. Vaccination with measles/mumps/rubella
(MMR) is recommended in children and seronegative adults
usually not before 2 years after HSCT but only in patients
without chronic GVHD or ongoing immunosuppression
[22,23].
The MMR vaccine has been given to infants awaiting renal
transplantation with good responses [104,105]. Children who
are transplant candidates and not yet vaccinated with MMR
should be vaccinated unless transplantation is imminent.
Other live vaccines. Very limited data exist on immunization
with Bacille Calmette–Gue´rin (BCG) vaccine in severely
immunocompromised patients and it is not recommended.
Yellow fever is a life-threatening infection primarily occur-
ring in South America and southern and central Africa. Rio
et al. [106] have reported three patients who were immu-
nized at 5 years after HSCT without severe side-effects
and this experience has since been expanded to 25
patients without any serious side-effects (B Rio, personal
communication). Immunization could be considered in
patients, who live in or must visit areas where yellow
fever is endemic.
Future directions
The number of patients with immunosuppressed states is
increasing. The advances in medical technology result in con-
stant changes in groups of patients undergoing intensive
immunosuppressive therapy. Furthermore, new immunosup-
pressive agents are being introduced and the types of thera-
pies given to these patients change. Therefore, prospective
clinical trials have to be performed to assess the efficacy of
vaccinations in these new cohorts.
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